The taxoids. Comparative clinical pharmacology and therapeutic potential.
about
Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cellsChemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative StressDocetaxel/anthracycline combinations for breast cancer treatmentMobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF.Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.Docetaxel-induced photolichenoid eruption.Synthesis of novel molecular probes inspired by harringtonolide.Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Effects of cell cycle inhibitors on tau phosphorylation in N2aTau3R cells.Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain.γ-tocotrienol enhances the chemosensitivity of human oral cancer cells to docetaxel through the downregulation of the expression of NF-κB-regulated anti-apoptotic gene products.Clinical trials and progress with paclitaxel in ovarian cancerPalmar-plantar erythrodysesthesia secondary to docetaxel chemotherapy: a case report.Long-term eradication of locally recurrent invasive follicular thyroid carcinoma after taxane-based concomitant chemoradiotherapy.Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cellsMaitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicityVascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancerPharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsAdvances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.Paclitaxel for non-small cell lung cancer.Docetaxel in advanced non-small cell lung cancer.The role of taxanes in the management of gastroesphageal cancerActivation of acetyl-coenzyme A carboxylase is involved in Taxol-induced ovarian cancer cell death.Docetaxel in the treatment of breast cancer: current experience and future prospects.Targeted drug delivery to mammalian mitochondria in living cells.Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancerA phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours.Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetrationBortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyDocetaxel for the post-surgery treatment of patients with node-positive breast cancerThe relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.Evidence for a distinct ligand binding site on tubulin discovered through inhibition by GDP of paclitaxel-induced tubulin assembly in the absence of exogenous GTP.Paraclinical evaluation of side-effects of Taxanes on auditory systemCardiovascular effects of noncardiovascular drugs.Taxanes: their impact on gynecologic malignancy.Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.Identification of mutations, gene expression changes and fusion transcripts by whole transcriptome RNAseq in docetaxel resistant prostate cancer cells
P2860
Q24317614-2A7B17FE-F6D6-4AAD-9A19-7CE09D103117Q26780547-593BAE1F-FDA3-4FE7-A091-668F188042EAQ28288899-2BDB0852-52EF-434A-AC46-FDFA1314952AQ33331475-8EE88E78-FB3D-4312-B032-3F432ABBC9C8Q33532808-AF669B5C-E1AC-4228-88EB-3AB3E9D63CD1Q33874080-10D2D41F-2962-405B-8B0D-8CE15438D364Q33887944-8BCC3C5A-57D5-4D50-B0D1-F0FCA399AE77Q33924515-026139DC-4BB3-448E-9EE7-E10E3A15F472Q33955039-9EF7A68C-BE6B-4D36-8824-224DD47821CDQ34468934-CB0BACF1-4E3B-4793-BCF8-872A3F8591D0Q34471481-660A642B-90F7-494A-8838-5C9336FD9D91Q34510070-608AF166-889B-4405-8E11-10698F4371F6Q34677631-98C84FCD-1462-4A89-AF7B-C0709F94D6DDQ35029319-73E4636D-3498-43A7-9513-1DF6E2B9723CQ35131712-A410BD77-712A-42F8-9331-D517CFB6A8F2Q35710628-CD13EE31-BBFA-4E94-B60F-716BD95502F9Q35747792-6E824B83-37A2-48A2-9250-093E0127CA1FQ35803848-BEE364E1-6F22-4600-AE41-89B219B3C09BQ35832903-C91F79C5-5CCE-44EF-9ACB-2C7DD489C0DCQ35841594-12F72665-1CA7-40D7-A6B2-CBF95EC9DDB8Q36066126-C5638144-860F-4D3A-9FC8-988BBA3E9C83Q36097240-4FD62044-D55C-4279-A3B2-15A8B87F7E8DQ36135360-8B06F8C3-FAA9-46DE-B84F-825339539AA9Q36235546-69CECA08-8F81-44DA-971E-26A05EA42FF7Q36316672-5BD67382-13FC-4380-8A04-D2114C4B8344Q36388489-33E39EFF-F054-458B-9C37-64A85F5E31EEQ36494207-A0D62090-F085-4AF3-A332-B44B98AFEB0EQ36621587-221406B4-4EBB-4350-8C9F-B099D54ECE02Q36667443-ACF38F38-2E3A-43C3-8DFB-B26CCC547E72Q36823602-7CAE5333-57FF-480C-8A87-59F18174E21FQ36824621-5A66379C-9621-4EB4-A99A-FA098F10CEF2Q37038979-2F91704D-E528-4C35-8AF9-F3EF91655F73Q37138037-1E019712-EFF7-44C4-8369-3810F8CF6944Q37210226-E8BDA710-31CC-437B-A57A-73E4A2D85013Q37413163-26B35815-9179-4BA2-AB65-5BF289681833Q37692801-E7A548B8-A333-4902-BD13-0BE140543F30Q38047388-52782889-5C5D-4489-8E9F-F3B66D8C7B8BQ38166071-6C826CC5-8FA8-4C97-8104-553C55CEC6F3Q38508027-92390CDC-6EA2-43A9-95D2-3681820A0AC4Q39206549-5D75E73F-BB6D-403A-AA27-0ECAA71A5612
P2860
The taxoids. Comparative clinical pharmacology and therapeutic potential.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@ast
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@en
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@nl
type
label
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@ast
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@en
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@nl
prefLabel
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@ast
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@en
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@nl
P1433
P1476
The taxoids. Comparative clinical pharmacology and therapeutic potential.
@en
P2093
E A Eisenhauer
J B Vermorken
P356
10.2165/00003495-199855010-00002
P577
1998-01-01T00:00:00Z
P6179
1027431780